The recommendations relate to the grading system currently suggested by the European Society of Cardiology and the American Heart Association, and were based on paediatric data only (class, level of evidence). The grading and voting process within the writing group is outlined in the executive summary2 in this special issue. Recommendations on PH therapy specifically in neonatal chronic lung disease and persistent pulmonary hypertension of the newborn,5 and PAH associated with congenital heart disease,4 are outlined in separate articles in this special issue.

AVT, acute vasodilator testing; AVR, acute vasoreactivity response; CCB, calcium channel blockers; COR, class of recommendation; HPAH, heritable pulmonary arterial hypertension; ICU, intensive care unit; iNO, inhaled nitric oxide; INR, international normalised ratio; IPAH, idiopathic pulmonary arterial hypertension; LOE, level of evidence; PAH, pulmonary arterial hypertension; PDE5, phosphodiesterase 5; PH, pulmonary hypertension; PHVD, Pulmonary hypertensive vascular disease; PPHN, persistent pulmonary hypertension of the newborn; RCT, randomised controlled trials